Me is closing its therapeutics division and will wind down ongoing clinical trials, the struggling genetic testing company ...

The FDA has removed a clinical hold on Novavax’s flu-Covid combination shot and standalone flu vaccine, less than a month ...

Rapt Therapeutics is officially shelving its mid-stage immunology candidate after a case of liver failure triggered clinical ...

Assertio Holdings responded to activist investor Alexander Parker after Parker's firm accused Assertio of fraud. The Buxton Helmsley Group on Friday released an open letter to Assertio’s stockholders, ...

The centerpiece of AbbVie’s $8.7 billion Cerevel acquisition just imploded. Emraclidine, a schizophrenia program expected to ...

Cigna said it will not pursue a merger with rival Humana after reports last month of renewed talks about a potential deal. Talks of a deal ...

The eye giant Alcon has launched an unlikely legal battle, suing a cell therapy startup that it invested in and claiming its shareholder rights are being violated as Aurion Biotech ...

Glucagon-like peptide-1 (GLP-1) receptor agonists have gained attention as potential treatments for a variety of ...

The FDA this week posted an untitled letter sent Oct. 17 to China-based active pharmaceutical ingredient (API) manufacturer ...

Amgen and AstraZeneca said on Friday that their asthma drug Tezspire reduced nasal congestion and the size of nasal polyps in patients with a different but sometimes related inflammatory condition ...

Eisai has slashed Leqembi's sales forecast by 25% this year, lowering the ceiling for one of the industry's most ...

In another sign that biopharma companies are slowing their early R&D efforts, Charles River Laboratories is shuttering more than a dozen sites. The service provider is working on “consolidating ...